Designed to expand PSMA PET imaging access for patients by increasing batch size by ~50% and enhancing supply resiliencePDUFA date set for March 6, 2026 BEDFORD, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) ...

The FDA has accepted for review the sNDA for deucravacitinib for the treatment of adults with active psoriatic arthritis.

A multinational biopharmaceutical corporation, Bristol-Myers Squibb Company (NYSE:BMY) is engaged in product discovery, ...

Submission is supported by 24-week results from the Phase 3b APEX study in adults with active psoriatic arthritis treated ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S.

Dr. Marty Makary, the Food and Drug Administration commissioner, wrote an article in the journal JAMA arguing that A.I. would “radically increase efficiency” in the process of deciding whether ...